ALZN Alzamend Neuro Inc
Company Analysis
Latest News
🟢 Alzamend Neuro is trading 7.5% up today on $25M Series D financing deal
Alzamend Neuro is trading 7.5% up today at $1.44, extending gains following a $25 million Series D Convertible Preferred Stock agreement with an affiliate of...
Alzamend Neuro Secures up to $25M in Financing via Series D Preferred Stock Sale
Alzamend Neuro entered into a Securities Purchase Agreement with an affiliate, Ault Lending, LLC, to sell up to $25 million of its newly designated Series D...
🔴 Alzamend Neuro is trading 7% down today with no clear company-specific catalyst found
Alzamend Neuro is trading at $1.22 (-6.87%) in pre-market, extending a downward move from its $1.31 close on July 31 despite a lack of company-specific...
🔴 Alzamend Neuro is trading 5.2% down today with no clear catalyst
Alzamend Neuro is trading 5.2% down at $1.27 today following a quiet news flow with no fresh, company-specific developments or filings identified this...
🔴 Alzamend Neuro is trading 5.2% down today with no company-specific catalyst
Alzamend Neuro is trading at $1.27 (-5.22%) in pre-market after a quiet session with no company-specific catalyst found in available news. • Broader markets...
🔴 Alzamend Neuro is trading 6% down today on an earnings preview projecting zero revenue and a $0.67 EPS loss
Alzamend Neuro is trading at $1.26 (-5.97%) as investors position themselves ahead of the company's July 28, 2026, earnings report. • The Q2 2026 earnings...
Alzamend Neuro Inc Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
For the fiscal period ending April 30, 2026, Alzamend Neuro is expected to report zero revenue and a consensus EPS loss of $0.67, with the stock currently...
🔴 Alzamend Neuro is trading 5.3% down today as annual report rally cools
Alzamend Neuro is trading 5.3% down at $1.26 in after-hours trading, giving back a portion of its regular-session gains as the rally sparked by its annual...
🟢 Alzamend Neuro is trading 6.4% up today after its annual report detailed trial timelines and funding requirements
Alzamend Neuro is trading at $1.34 (6.4% up) after investors digested its latest annual report detailing an $8.8 million loss and funding shortfall for...
Alzamend Neuro Reports $8.8M Loss, Warns of Funding Shortfall for Trials
Alzamend Neuro, Inc. filed its fiscal 2026 Annual Report for the year ending April 30, 2026. The company expects topline results for its AL001 Phase II Bipolar...
🟢 Alzamend Neuro is trading 5.6% up today amid micro-cap volatility and risk-on sentiment
Alzamend Neuro is trading 5.6% up today at $1.33 as micro-cap volatility and a risk-on market environment drive gains despite a lack of company-specific...
🟢 Alzamend Neuro is trading 5.8% up today amid low-cap volatility
Alzamend Neuro is trading 5.8% up at $1.28 today amid low-cap volatility and a lack of fresh company-specific catalysts. • There are no new headlines or...
🔴 Alzamend Neuro is trading 5.7% down today as investors rotate away from small-cap biotech
Alzamend Neuro is trading at $1.16 (5.7% down) as recent macro-driven gains ease and investors rotate away from smaller biotech names. • The move aligns with...
🔴 Alzamend Neuro is trading 6.6% down today as macro-driven gains fade amid biotech rotation
Alzamend Neuro is trading 6.6% down at $1.13 as recent gains driven by softer inflation data and improving macro sentiment fade. • Investors are rotating out...
🔴 Alzamend Neuro is trading 16.4% down today as it reverses its recent macro-driven rally
Alzamend Neuro is trading 16.4% down at $1.01 in pre-market as the stock reverses its recent macro-driven rally. • On July 14, 2026, the stock closed up about...
🟢 Alzamend Neuro is trading 5.2% up today as growth stocks rally on softer inflation data
Alzamend Neuro is trading at $1.22, up 5.2% today, as the stock rebounds from recent selling pressure driven by geopolitical tensions and sector-wide...
🔴 Alzamend Neuro is trading 5.7% down today, extending losses amid biotech sector pressure and geopolitical tensions
Alzamend Neuro is trading 5.7% down at $1.09 in pre-market, extending weakness from the prior session amid broader biotech-sector pressure. • Shares fell...
🔴 Alzamend Neuro is trading 5.9% down today amid biotech weakness and geopolitical tensions
Alzamend Neuro is trading 5.9% down today at $1.12 amid broader biotech sector weakness and risk-off sentiment tied to escalating U.S.–Iran geopolitical...
🔴 Alzamend Neuro Drops 5.2% Amid Reports of Significant Net Loss
• Alzamend Neuro is trading 5.2% down today at $1.09. • The company recently reported a net loss of $2.7 million, with an earnings per share (EPS) of $(1.28),...
🔴 ALZN is trading 5.85% down today on continued weakness following Alzheimer’s trial data disclosures
ALZN is trading at $1.08 (5.85% down) in after-hours, extending recent weakness following a sharp drop tied to new Alzheimer’s trial data disclosures. •...